Sorafenib News and Research

RSS
Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).
Researchers determine the novel medical target of angiogenesis for ccRCC patients

Researchers determine the novel medical target of angiogenesis for ccRCC patients

Study identifies novel targets for treating sorafenib-resistant hepatocellular carcinoma

Study identifies novel targets for treating sorafenib-resistant hepatocellular carcinoma

Study identifies new targets for treating sorafenib-resistant hepatocellular carcinoma using CRISPR-Cas9 screening

Study identifies new targets for treating sorafenib-resistant hepatocellular carcinoma using CRISPR-Cas9 screening

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.